复发性上皮性卵巢癌治疗时机及治疗方案的选择对预后的影响  

Effect of Treatment Timepoint and Regime on Prognosis of Recurrent Epithelial Ovarian Cancer

作　　者：夏杨[1] 吴海根[1] 吴澜[1] 都三平[1] 兰秋红[1] 

机构地区：[1]江西省妇幼保健院,330006

出　　处：《实用癌症杂志》2016年第12期2047-2050,共4页The Practical Journal of Cancer

摘　　要：目的研究临床干预的时机以及治疗方案对复发性上皮性卵巢癌患者预后的影响。方法收集复发性上皮性卵巢癌病例43例临床资料进行回顾性分析,并随访患者的2年生存率;按治疗时机和治疗方案分为2个研究组,A组中21例2次CA125升高即开始治疗,22例出现临床症状后开始治疗;B组中20例采用手术+化疗治疗方案,23例采用单纯化疗。通过生存率的比较研究治疗时机及治疗方案对预后的影响,并对与生存率相关的因素进行多因素分析。结果 2次CA125升高即开始治疗与出现临床症状后开始治疗相比,2年生存率差异无统计学意义(P>0.05);而复发后采用手术+化疗治疗方案与单纯化疗相比,采用手术+化疗治疗方案患者的2年生存率显著高于单纯化疗,差异具有统计学意义(P<0.05)。复发性上皮性卵巢癌生存率与CA125水平升高无显著相关性(P>0.05)。结论复发性上皮性卵巢癌再次治疗时机无论从CA125升高开始,还是从出现临床症状时开始对患者的2年生存率无明显影响。治疗方案上采用手术+化疗治疗方案的患者预后优于单纯化疗。Objective To evaluate the effect of treatment timepoint and treatment regime on the prognosis of recurrent epithelial ovarian cancer. Methods Retrospective analysis of clinical data of 43 patients with recurrent epithelial ovarian cancer were conducted,2-year survival rate were recorded during follow up. All patients were divided into 2 groups based on treatment timepoint and treatment regime, In group A,21 patients were treated when CA125 increase was noted for the second time,22 pa- tients were treated when clinical symptoms were noted;In group B,20 patients were treated with surgery plus chemotherapy, 23 patients were treated with chemotherapy. Survival rate was compared to evaluate the influence of treatment timepoint and treatment regime on the prognosis. And the multivariate analysis was conducted about the factors related to survival rate. Results There was no significant difference in 2-year survival rate between the patients started treatment when CA125 increase was noted for the second time and those started treatment when clinical symptoms were noted（ P 〉 0.05 ） ;While 2-year survival rate in the patients treated by surgery plus chemotherapy was significantly higher than those received chemotherapy alone （P 〈 0.05 ）. There was no significant correlation between survival rate of recurrent epithelial ovarian cancer and elevated CA125 level（ P 〉 0.05 ）. Conclu- sion Treatment timepoint of recurrent epithelial ovarian cancer（ either treatment started when the elevated CA125 level was not-ed for the second time, or treatment started when clinical symptoms was noted） has no significant influence on the 2-year survival rate, and the prognosis of patients treated with surgery plus chemotherapy is better than those received chemotherapy alone.

关 键 词：复发性上皮性卵巢癌 CA125 治疗时机 治疗方案 预后 

分 类 号：R737.31[医药卫生—肿瘤]